Department of Obstetrics & Gynecology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Nursing, Jerusalem College of Technology, Jerusalem, Israel.
BJOG. 2022 Jan;129(2):248-255. doi: 10.1111/1471-0528.16941. Epub 2021 Oct 6.
To evaluate the impact of Covid-19 vaccination (Pfizer-BioNTech BNT162b2) during the third trimester of pregnancy on maternal and neonatal outcomes.
A multicentre, retrospective computerised database.
Women who gave birth at >24 weeks of gestation in Israel, between January and April 2021, with full records of Covid-19 disease and vaccination status.
Women who received two doses of the vaccine were compared with unvaccinated women. Women who were recorded as having disease or a positive Covid-19 polymerase chain reaction (PCR) swab during pregnancy or delivery were excluded from both study groups. Univariate analysis was followed by multivariate logistic regression.
Composite adverse maternal outcomes. Secondary outcomes were vaccination rate and composite adverse neonatal outcomes.
The overall uptake of one or both vaccines was 40.2%; 712 women who received two doses of the Covid-19 vaccine were compared with 1063 unvaccinated women. Maternal composite outcomes were comparable between the groups; however, women who received the vaccine had higher rates of elective caesarean deliveries (CDs) and lower rates of vacuum deliveries. An adjusted multivariable logistic regression analysis demonstrated that Covid-19 vaccination was not associated with maternal composite adverse outcome (aOR 0.8, 95% CI 0.61-1.03); a significant reduction in the risk for neonatal composite adverse outcomes was observed (aOR 0.5, 95% CI 0.36-0.74).
In a motivated population covered by a National Health Insurance Plan, we found a 40.2% rate of vaccination for the Covid-19 vaccine during the third trimester of pregnancy, which was not associated with adverse maternal outcomes and, moreover, decreased the risk for neonatal adverse outcomes.
Covid-19 vaccine during pregnancy is safe for both mother and fetus.
评估妊娠晚期接种(辉瑞-生物技术公司的 BNT162b2)新冠疫苗对母婴结局的影响。
多中心、回顾性计算机化数据库研究。
2021 年 1 月至 4 月期间,在以色列分娩且妊娠 24 周以上、有完整新冠疾病和疫苗接种记录的女性。
比较接种两剂疫苗的女性与未接种疫苗的女性。两组均排除妊娠或分娩期间记录有疾病或新冠病毒聚合酶链反应(PCR)拭子阳性的女性。采用单变量分析,然后进行多变量逻辑回归。
复合不良母婴结局。次要结局指标为疫苗接种率和复合不良新生儿结局。
单剂或双剂疫苗总接种率为 40.2%;比较了 712 名接种两剂新冠疫苗的女性和 1063 名未接种疫苗的女性。两组的母婴复合结局相当,但接种疫苗的女性选择性剖宫产(CD)率更高,真空分娩率更低。调整后的多变量逻辑回归分析表明,新冠疫苗接种与母婴复合不良结局无关(调整比值比[aOR]0.8,95%置信区间[CI]0.61-1.03);新生儿复合不良结局的风险显著降低(aOR 0.5,95%CI 0.36-0.74)。
在一个有国家健康保险计划覆盖的积极参与人群中,我们发现妊娠晚期新冠疫苗接种率为 40.2%,对母婴均安全,且降低了新生儿不良结局的风险。
妊娠期间接种新冠疫苗对母婴均安全。